Matching articles for "emtricitabine/tenofovir"
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • August 26, 2019; (Issue 1579)
The FDA has approved Dovato (ViiV), a fixed-dose
combination of the integrase strand transfer inhibitor
(INSTI) dolutegravir (Tivicay) and the nucleoside
reverse transcriptase inhibitor (NRTI)...
The FDA has approved Dovato (ViiV), a fixed-dose
combination of the integrase strand transfer inhibitor
(INSTI) dolutegravir (Tivicay) and the nucleoside
reverse transcriptase inhibitor (NRTI) lamivudine
(Epivir, and generics), as a once-daily complete
regimen for treatment of adults with HIV-1 infection
who are antiretroviral-treatment naive and have no
known substitutions associated with resistance
to either drug. Dolutegravir/lamivudine is the first
complete regimen to be approved by the FDA for
initial treatment of HIV-1 infection that contains 2
rather than 3 antiretroviral drugs. Juluca, a fixed-dose
combination of dolutegravir and the non-nucleoside
reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant), was approved in 2018 for treatment of
adults with HIV-1 infection already taking a stable,
suppressive antiretroviral regimen.
Symfi, Symfi Lo, and Cimduo for HIV (online only)
The Medical Letter on Drugs and Therapeutics • January 14, 2019; (Issue 1563)
The FDA has approved three new once-daily fixed-dose
antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the
non-nucleoside reverse transcriptase inhibitor...
The FDA has approved three new once-daily fixed-dose
antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the
non-nucleoside reverse transcriptase inhibitor (NNRTI)
efavirenz and the nucleoside reverse transcriptase
inhibitors (NRTIs) lamivudine and tenofovir disoproxil
fumarate (TDF) and were approved as complete
antiretroviral regimens. Symfi Lo contains a lower
dose of efavirenz than both Symfi and Atripla, a fixed-dose
combination of efavirenz, TDF, and the NRTI
emtricitabine that was approved in 2006. Cimduo
(Mylan), which contains lamivudine and TDF, was
approved for use in combination with other antiretroviral
drugs. All three new products are marketed as less
expensive alternatives to other available fixed-dose
antiretroviral combinations (see Table 1).
Biktarvy - Another INSTI-Based Combination for HIV
The Medical Letter on Drugs and Therapeutics • August 13, 2018; (Issue 1553)
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs)...
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide (TAF), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who are antiretroviral-naive or who have
been virologically suppressed on a stable antiretroviral
regimen for ≥3 months with no history of treatment
failure and no known substitutions associated with
resistance to any component of the combination.
Triumeq: A 3-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • January 5, 2015; (Issue 1459)
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir...
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir and lamivudine, for once-daily treatment of
HIV-1 infection. Dolutegravir (Tivicay) was approved
as a single agent in 2013.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • February 1, 2014; (Issue 138)
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Dolutegravir (Tivicay) for HIV
The Medical Letter on Drugs and Therapeutics • September 30, 2013; (Issue 1426)
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years...
The FDA has approved dolutegravir (doll-you-TEG-rah-veer;
Tivicay – Viiv Healthcare), an integrase strand
transfer inhibitor (INSTI), for treatment of HIV-1 infection
in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir
and elvitegravir were approved earlier.
A 4-Drug Combination (Stribild) for HIV
The Medical Letter on Drugs and Therapeutics • November 26, 2012; (Issue 1404)
The FDA has approved a fixed-dose combination of
the integrase strand transfer inhibitor (INSTI) elvitegravir,
the pharmacokinetic enhancer cobicistat, and
the nucleoside/nucleotide reverse transcriptase...
The FDA has approved a fixed-dose combination of
the integrase strand transfer inhibitor (INSTI) elvitegravir,
the pharmacokinetic enhancer cobicistat, and
the nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) emtricitabine and tenofovir disoproxil
fumarate (Stribild – Gilead) for treatment of HIV-1
infection in antiretroviral treament-naïve adults.
Elvitegravir is the second INSTI to be approved by the
FDA for use in HIV treatment; raltegravir (Isentress)
was the first.
Rilpivirine (Edurant) - A New Drug for HIV Infection
The Medical Letter on Drugs and Therapeutics • August 22, 2011; (Issue 1371)
The FDA has approved rilpivirine (Edurant –
Janssen), a non-nucleoside reverse transcriptase
inhibitor (NNRTI), for use with other antiretroviral
agents for treatment of HIV-1 infection in...
The FDA has approved rilpivirine (Edurant –
Janssen), a non-nucleoside reverse transcriptase
inhibitor (NNRTI), for use with other antiretroviral
agents for treatment of HIV-1 infection in treatment-naive
adults. Rilpivirine is also available in a fixed-dose
combination with emtricitabine and tenofovir
(Complera – Gilead).